TradingKey – Amgen closed at $414.61 on September 25, a 2.11% gain. Their pipeline received an infusion of new positive data. The first is from the topline data of the Phase 3 study of dazodalibep for the treatment of Sjögren’s disease. Positive results from this study add a new catalyst to Amgen’s pipeline. IMDELLTRA and MariTide add longer term opportunities to Amgen’s pipeline. With positive results from the pipeline balancing biosimilar competition affecting older products, Amgen’s stock has rebounded from September lows.